Celldex (CLDX) Reports Q2 Loss of $0.33

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DVLT

Go back to Celldex (CLDX) Reports Q2 Loss of $0.33

Cantor Fitzgerald Cuts Price Target on Celldex (CLDX) to $31 Following Rintega Filing Delay

August 11, 2015 10:10 AM EDT

Cantor Fitzgerald maintained a Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $31.00 (from $38.00), following its decision to delay BLA filing for Rintega. Analyst Mara Goldstein said that filing for Rintega is not likely until the completion of ACT IV. ACT IV is expected... More

Roth Capital Trims PT on Celldex (CLDX) to $39 Following Q2 Results; Would be Buyers on Weakness

August 11, 2015 8:11 AM EDT

Roth Capital trims its price target on Celldex Therapeutics (Nasdaq: CLDX) from $43 down to $39 following Q2 results issued after markets closed Monday.

Analyst Joseph Pantginis commented, The key point to the 2Q15 results call, which we believe will drive perception for the... More

Brean Capital Cuts Price Target on Celldex (CLDX) Following Talks with FDA

August 11, 2015 7:07 AM EDT

Brean Capital maintained a Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $31.00 (from $35.00), following company talks with the FDA. CLDX has received enough feedback to conclude that it will not file Rintega for Accelerated Approval in recurrent GBM.

Analyst... More

Cowen Cuts Price Target on Celldex (CLDX) Following 2Q and Clinical Update

August 11, 2015 6:58 AM EDT

Cowen maintained an Outperform rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $28.00 (from $34.00), following 2Q earnings and clinical update. CLDX has decided not to file for acceleration of Rintega. Analyst Boris Peaker is disappointed by the rindo filing... More